This study from Germany carried out a multicentre,
double-blind, randomised, placebo-controlled study, on the safety and
efficacy of rivastigmine in cognitively impaired MS patients. 86
patients were enrolled in the study. Primary endpoints included the
change in total recall scores of the selective reminding test (SRT) from
baseline to 16 weeks.
Overall, they found that there was a
tendency for improvement of total recall by rivastigmine, however, this
was not siginificant because of lack of statistical power. Other outcome
measures provided no evidence supporting benefits of rivastigmine over
placebo. Treatment with rivastigmine was safe and well tolerated.
Authors: Mäurer M, Ortler S, Baier M
Source: Mult Scler. 2012 Oct 15. [Epub ahead of print]
Read the abstract